안녕하세요 리가켐바이오 IR팀입니다. 당사 ADC 플랫폼 기술이전 파트너사인 소티오(SOTIO Biotech)가 최근 당사 플랫폼 기술이 적용된 LRRC15 A…
LinkedIn
#osteosarcoma #adc #sarcoma #indacceptance #drugdevelopment #clinicaltrials #oncologyresearch | SOTIO Biotech
The U.S. Food and Drug Administration (FDA) has accepted our investigational new drug (IND) application for SOT106, enabling a first-in-human Phase 1/2 trial in patients with #osteosarcoma and soft tissue sarcoma. SOT106 is an investigational antibody-drug conjugate (#ADC) targeting LRRC15, a clini…
